REFERENCES
1. Khan, M., Adil, S.F., Alkhathlan, H.Z., Tahir, M.N., Saif, S., Khan,
M., & Khan, S.T., (2020). COVID-19: a global challenge with old
history, epidemiology and progress so far. Molecules 26 , 39.
2. Hu, B., Guo, H., Zhou, P., & Shi, Z.L. (2021). Characteristics of
SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19 , 141-154.
3. Parker, E.P.K., Shrotri, M., & Kampmann, B. (2020). Keeping track of
the SARS-CoV-2 vaccine pipeline. Nat. Rev. Immunol. 20(11) , 650.
4. Chen, W.H., Hotez, P.J., & Bottazzi, M.E. (2020). Potential for
developing a SARS-CoV receptor-binding domain (RBD) recombinant protein
as a heterologous human vaccine against coronavirus infectious disease
(COVID)-19. Hum. Vaccin. Immunother. 16(6) , 1239-1242.
5. Wu, S., Zhong, G., Zhang, J., Shuai, L., & Zhang, Z., et al. (2020).
A single dose of an adenovirus-vectored vaccine provides protection
against SARS-CoV-2 challenge. Nat. Commun. 11(1) , 4081.
6. Kyriakidis, N.C., López-Cortés, A., González, E.V., Grimaldos, A.B.,
& Prado, E.O., (2021). SARS-CoV-2 vaccines strategies: A comprehensive
review of phase 3 candidates. NPJ Vaccines 6 , 28.
7. Cobey, S., Larremore, D.B., Grad, Y.H., & Lipsitch, M. (2021).
Concerns about SARS-CoV-2 evolution should not hold back efforts to
expand vaccination. Nat. Rev. Immunol. 21 , 330-335.
8. Rashid, F., Dzakah, E.E., Wang, H., & Tang, S. (2021). The ORF8
protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated
immune evasion by antagonizing production of interferon beta.Virus Res. 296 , 198350.
9. Li, J.Y., Liao, C.H., Wang, Q., Tan, Y.J., Luo, R., Qiu, Y., & Ge,
X.Y. (2020). The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2
inhibit type I interferon signaling pathway. Virus Res. 286 ,
198074.
10. Flower, T.G., Buffalo, C.Z., Hooy, R.M., Allaire, M., Ren, X., &
Hurley, J.H. (2021). Structure of SARS-CoV-2 ORF8, a rapidly evolving
immune evasion protein. Proc. Natl. Acad. Sci. U.S.A. 118 ,
e2021785118.
11. Can, H., Köseoğlu, A.E., Alak, S.E., Güvendi, M., Döşkaya, M.,
Karakavuk, M., Gürüz, A.Y., & Ün, C. (2020). In silico discovery of
antigenic proteins and epitopes of SARS‑CoV‑2 for the development of a
vaccine or a diagnostic approach for COVID‑19. Sci. Rep. 10 ,
22387.
12. Park, M.D., (2020). Immune evasion via SARS-CoV-2 ORF8 protein?
Nat. Rev. Immunol. 20 , 408.
13. Perrie, Y., Mohammed, A.R., Kirby, D.J., McNeil, S.E., & Bramwell,
V.W. (2008). Vaccine adjuvant systems: enhancing the efficacy of
sub-unit protein antigens. Int. J. Pharm. 364(2) , 272-280.
14. Yu, W., & Hu, T. (2016). Conjugation with an inulin-chitosan
adjuvant markedly improves the immunogenicity of Mycobacterium
tuberculosis CFP10-TB10.4 fusion protein. Mol. Pharm. 13 ,
3626-3635.
15. Yin, Y., Yu, W., Li, Y., Liu, K., & Zai, X., et al. (2019).
Self-conjugated protective antigen elicits strong and durable protective
antibody response against anthrax. Int. J. Biol. Macromol. 137 ,
790-800.
16. Wang, K., Zhou, L., Zhang, X., Song, C., Chen, T., & Li, J. (2019).
Hepatitis E vaccine candidate harboring a non-particulate immunogen of
E2 fused with CRM197 fragment A. Antiviral Res.
164 , 154-161.
17. Hu, S., Yu, W., Hu, C., Wei, D., Shen, L., Hu, T., & Yi, Y. (2017).
Conjugation of the CRM197-inulin conjugate significantly
increases the immunogenicity of Mycobacterium tuberculosisCFP10-TB10.4 fusion protein. Bioorg. Med. Chem. 25 , 5968-5974.
18. Sun, X., Yu, W., Pang, Q., & Hu, T. (2017). Conjugation reaction
with 8-arm PEG markedly improves the immunogenicity ofMycobacterium tuberculosis CFP10-TB10.4 fusion protein.Bioconjugate Chem. 28 , 1658-1668.
19. He, Y., Yu, W., Xiao, L., Shen, L., Qi, J., & Hu, T. (2021).
Conjugation of Zika virus EDIII with CRM197, 8-arm PEG
and mannan for development of an effective Zika virus vaccine.Int. J. Biol. Macromol. 190, 713-721.
20. Wei, D., Yu, W., Hu, C., Shen, L., & Hu, T. (2018). The phenyl
linker markedly increases the immunogenicity of the pneumococcal
polysaccharide conjugate vaccine. Biotechnol. Lett. 40 ,
1263-1270.
21. Bardotti, A., Averani, G., Berti, F., Berti, S., Galli, C.,
Giannini, S., Fabbri, B., Proietti, D., Ravenscroft, N., & Ricci, S.
(2005) Size determination of bacterial capsular oligosaccharides used to
prepare conjugate vaccines against Neisseria meningitidis groups Y and
W135. Vaccine 23 , 1887-1899.